Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Synpromics, uniQure deal

    Synpromics Ltd., Edinburgh, U.K. uniQure N.V. (NASDAQ:QURE), Amsterdam, the Netherlands Business: Drug delivery, Hepatic Synpromics and uniQure partnered to develop synthetic promoters that will increase the …

    Published on 3/23/2015
  • Universite catholique de Louvain, arGEN-X deal

    Universite catholique de Louvain, Louvain-la-Neuve, Belgium arGEN-X N.V. (Euronext:ARGX), Breda, the Netherlands Business: Cancer arGEN-X exercised an exclusive option to license worldwide rights to a preclinical mAb …

    Published on 3/23/2015
  • XO1, J&J deal

    XO1 Ltd., Cambridge, U.K. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cardiovascular The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson acquired XO1, which is developing preclinical anticoagulant…

    Published on 3/23/2015
  • 14M Genomics, EORTC deal

    14M Genomics Ltd., Hinxton, U.K. European Organization for Research and Treatment of Cancer, Brussels, Belgium Business: Cancer 14M Genomics and the European Organization for Research and Treatment of Cancer (EORTC) …

    Published on 3/16/2015
  • Anaconda Pharma, Biota Pharmaceuticals deal

    Anaconda Pharma Ltd., Villejuif, France Biota Pharmaceuticals Inc. (NASDAQ:BOTA), Alpharetta, Ga. Business: Infectious Biota is acquiring Anaconda for $8 million in cash and 3.5 million Biota shares, valued at $8.7 …

    Published on 3/16/2015
  • Becton Dickinson and Co, DecisionQ, EKF Diagnostics, Greenville Health System deal

    Becton Dickinson and Co. (NYSE:BDX), Franklin Lakes, N.J. DecisionQ Corp., Arlington, Va. EKF Diagnostics Holdings plc (LSE:EKF), Penarth, U.K. Greenville Health System, Greenville, S.C. Business: Cancer EKF Diagnostics…

    Published on 3/16/2015
  • Covis, Concordia Healthcare deal

    Covis Pharma S.a.r.l., Zug, Switzerland Concordia Healthcare Corp. (TSX:CXR;OTCQX:CHEHF), Oakville, Ontario Business: Infectious, Cancer, Cardiovascular Concordia will acquire Covis commercial assets, specifically its …

    Published on 3/16/2015
  • Duke University, Annias Immunotherapeutics deal

    Duke University, Durham, N.C. Annias Immunotherapeutics Inc., Chapel Hill, N.C. Business: Cancer Duke granted newco Annias exclusive, worldwide rights to develop and commercialize IP covering immune preconditioning …

    Published on 3/16/2015
  • Epizyme Inc, Eisai deal

    Epizyme Inc. (NASDAQ:EPZM), Cambridge, Mass. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Cancer Epizyme paid $40 million up front to Eisai to regain worldwide rights, excluding Japan, to EPZ-6438. The selective …

    Published on 3/16/2015
  • ExpreS2ion, Ludwig Maximilian University of Munich deal

    ExpreS2ion Biotechnology ApS, Horsholm, Denmark Ludwig Maximilian University of Munich, Munich, Germany Business: Proteomics ExpreS2ion granted the university a research license for the ExpreS2 recombinant protein …

    Published on 3/16/2015
  • Gold Coast Therapeutics, Insys deal

    Gold Coast Therapeutics Inc., Evanston, Ill. Insys Therapeutics Inc. (NASDAQ:INSY), Phoenix, Ariz. Business: Genitourinary Gold Coast granted Insys an exclusive sublicense to develop a combination of cromolyn sodium and…

    Published on 3/16/2015
  • Johnson & Johnso, Cardinal Health deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Cardinal Health Inc. (NYSE:CAH), Dublin, Ohio Business: Cardiovascular Johnson & Johnsons Ethicon Inc. subsidiary will sell its Cordis cardiology and endovascular …

    Published on 3/16/2015
  • Johnson & Johnso, Kura Oncology deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Kura Oncology Inc., La Jolla, Calif. Business: Cancer Johnson & Johnsons Janssen Pharmaceutica N.V. unit granted Kura exclusive, worldwide rights to develop and …

    Published on 3/16/2015
  • NanoCarrier Co. Ltd, Chugai deal

    NanoCarrier Co. Ltd. (Tokyo:4571), Kashiwa, Japan Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Business: Cancer, Drug delivery NanoCarrier and Chugai partnered to develop a short interfering RNA cancer drug…

    Published on 3/16/2015
  • OnCore Biopharma, Tekmira deal

    OnCore Biopharma Inc., Doylestown, Pa. Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR), Burnaby, B.C. Business: Infectious Tekmira completed its merger with OnCore. The merged company will operate as Tekmira and will …

    Published on 3/16/2015
  • Onxeo S.A, Dara BioSciences deal

    Onxeo S.A. (Euronext:ONXEO;CSE:ONXEO), Paris, France Dara BioSciences Inc. (NASDAQ:DARA), Raleigh, N.C. Business: Infectious Onxeo granted Dara exclusive rights in the U.S. to commercialize Oravig miconazole, which is …

    Published on 3/16/2015
  • Orca Pharmaceuticals, AstraZeneca deal

    Orca Pharmaceuticals Ltd., Oxford, U.K. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Autoimmune AstraZeneca will gain access to Orcas inhibitors of RAR-related orphan receptor C (RORC; RORgamma). According…

    Published on 3/16/2015
  • Pharmaxis Ltd, Boehringer Ingelheim deal

    Pharmaxis Ltd. (ASX:PXS;Pink:PXSLY), Frenchs Forest, Australia Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Hepatic, Inflammation Boehringer Ingelheim received an exclusive option to license worldwide rights …

    Published on 3/16/2015
  • R-Tech Ueno Ltd, Sucampo deal

    R-Tech Ueno Ltd. (JASDAQ:4573), Tokyo, Japan Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP), Bethesda, Md. Business: Ophthalmic Sucampo returned all rights to unoprostone isopropyl (UF-021) to R-Tech after the product …

    Published on 3/16/2015
  • Salix Pharmaceuticals Ltd, Endo deal

    Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Endo International plc (NASDAQ:ENDP;TSX:ENL), Dublin, Ireland Business: Gastrointestinal Endo submitted a proposal to acquire Salix for $175 per share in cash and …

    Published on 3/16/2015
  • Salk Institute for Biological Studies, Mitobridge deal

    Salk Institute for Biological Studies, La Jolla, Calif. Mitobridge Inc., Cambridge, Mass. Business: Pharmaceuticals The institute granted Mitobridge exclusive, worldwide rights to develop and commercialize technology …

    Published on 3/16/2015
  • Theratechnologies Inc, AOP Orphan deal

    Theratechnologies Inc. (TSX:TH), Montreal, Quebec AOP Orphan Pharmaceuticals AG, Vienna, Austria Business: Endocrine/Metabolic Theratechnologies granted AOP Orphan exclusive rights to develop and commercialize Egrifta …

    Published on 3/16/2015
  • TransTech, Calithera Biosciences deal

    TransTech Pharma LLC, High Point, N.C. Calithera Biosciences Inc. (NASDAQ:CALA), South San Francisco, Calif. Business: Cancer TransTech granted cancer company Calithera exclusive, worldwide rights to develop and …

    Published on 3/16/2015
  • Valneva S, InFlectis deal

    Valneva SE (Euronext:VLA;VSE:VLA), Lyon, France InFlectis BioScience, Nantes, France Business: High throughput screening Valneva granted InFlectis exclusive, worldwide rights to the protein-protein interaction drug …

    Published on 3/16/2015
  • Zeta Acquisition, Kura Oncology deal

    Zeta Acquisition Corp. III, Des Moines, Iowa Kura Oncology Inc., La Jolla, Calif. Business: Cancer Kura Oncology completed its reverse-merger with shell company Zeta Acquisition Corp. III. The non-trading public company…

    Published on 3/16/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993